Nubeqa (Darolutamide)

Darolutamide, the active ingredient in Nubeqa, is an androgen receptor antagonist presented as a tablet for oral use. It treats non‑metastatic castration‑resistant prostate cancer in men who have previously received androgen‑deprivation therapy. GNH USA supplies Nubeqa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

GNH USA supplies Nubeqa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Nubeqa is an androgen‑receptor targeting therapy indicated for prostate‑cancer related indications.

- Non‑metastatic castration‑resistant prostate cancer (nmCRPC): delays metastasis and improves overall survival. - Metastatic castration‑resistant prostate cancer (mCRP​C): used in combination with androgen‑deprivation therapy to extend progression‑free survival. - High‑risk high‑grade prostate cancer: provides additional hormonal control when standard ADT is insufficient. - Post‑surgical resection of prostate tumour tissue in select patients: helps maintain low testosterone levels. - Advanced treatment resistant prostate cancer cases where other AR‑ ant­​s­​trogens have failed.

Common Side Effects: - Fatigue  - Di­ t ​    ​       …

Serious or Rare Side Effects: -  ...  

Nucle    

Major